Skip to main content

Oragenics Inc

OGEN
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0001174940

No open-market purchases or sales by Oragenics Inc insiders were filed in the last 90 days; 17 institutions reported holding it in 13F filings for Q2 2026, worth $39.2K in total; no superinvestor holds it.

Q4 2022 vs. Q3 2022

How the institutions holding Oragenics Inc changed between Q3 2022 and Q4 2022.

All holders in Q4 2022All holders in Q3 2022

13F holders of OGEN: Q3 2022 compared with Q4 2022
MeasureQ3 2022Q4 2022Change
Holders2931+2
Shares10.9M10.3M−653.8K (−6.0%)
Value$2.48M$1.08M−$1.40M (−56.4%)

New holders (10)

Institutions that held Oragenics Inc at the end of Q4 2022 but not at the end of Q3 2022.

Institutions new to OGEN in Q4 2022
InstitutionSharesValue% of portfolio
Susquehanna International Group, LLP146,953$15.4K0.00%
Citadel Advisors LLC86,698$9.11K0.00%
Raymond James & Associates33,853$3.56K0.00%
Cerity Partners LLC10,155$1.07K0.00%
Strategies Wealth Advisors, LLC10,001$1.05K0.00%
American Financial Group Inc13,540$1.00K0.00%
Bank of America Corp6,902$7250.00%
Morgan Stanley9$10.00%
Royal Bank of Canada103$00.00%
Corrado Advisors, LLC1$00.00%

Sold out (8)

Institutions that held Oragenics Inc at the end of Q3 2022 and filed for Q4 2022 without it.

Institutions that sold out of OGEN in Q4 2022
InstitutionShares, Q3 2022Value, Q3 2022
Millennium Management LLC107,559$24.0K
HighTower Advisors, LLC89,309$20.0K
Jane Street Group, LLC57,393$13.0K
Virtu Financial LLC31,307$7.00K
Grimes & Company, Inc.12,122$3.00K
HRT Financial LP12,717$2.00K
TSFG, LLC3,000$1.00K
UBS Group AG2,072$0